Dupont Capital Management Corp grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 70.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,591 shares of the biotechnology company’s stock after purchasing an additional 3,542 shares during the period. Dupont Capital Management Corp’s holdings in BioMarin Pharmaceutical were worth $732,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BB&T Corp raised its stake in shares of BioMarin Pharmaceutical by 7.3% during the third quarter. BB&T Corp now owns 16,093 shares of the biotechnology company’s stock valued at $1,561,000 after purchasing an additional 1,100 shares during the period. Gateway Investment Advisers LLC raised its stake in shares of BioMarin Pharmaceutical by 41.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 19,644 shares of the biotechnology company’s stock valued at $1,673,000 after purchasing an additional 5,772 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of BioMarin Pharmaceutical by 13.9% during the third quarter. DekaBank Deutsche Girozentrale now owns 82,664 shares of the biotechnology company’s stock valued at $8,294,000 after purchasing an additional 10,098 shares during the period. Comerica Bank raised its stake in shares of BioMarin Pharmaceutical by 5.9% during the third quarter. Comerica Bank now owns 10,096 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 565 shares during the period. Finally, IFM Investors Pty Ltd raised its stake in shares of BioMarin Pharmaceutical by 13.0% during the fourth quarter. IFM Investors Pty Ltd now owns 10,225 shares of the biotechnology company’s stock valued at $871,000 after purchasing an additional 1,177 shares during the period.
A number of analysts have recently issued reports on the stock. Cantor Fitzgerald set a $126.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Friday, October 26th. Raymond James lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $83.16 price objective on the stock. in a research note on Wednesday, January 2nd. Canaccord Genuity lifted their price objective on shares of BioMarin Pharmaceutical from $113.00 to $116.00 and gave the company a “buy” rating in a research note on Tuesday, October 23rd. BidaskClub lowered shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, November 8th. Finally, Wedbush restated an “outperform” rating and issued a $127.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $113.34.
Shares of NASDAQ:BMRN opened at $95.25 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.87 and a quick ratio of 2.26. The firm has a market capitalization of $17.13 billion, a P/E ratio of -142.16 and a beta of 1.63. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $106.74.
In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 2,150 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, December 27th. The shares were sold at an average price of $82.53, for a total value of $177,439.50. Following the completion of the transaction, the director now owns 21,310 shares of the company’s stock, valued at $1,758,714.30. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $98.63, for a total transaction of $394,520.00. Following the completion of the transaction, the chief executive officer now directly owns 292,290 shares of the company’s stock, valued at approximately $28,828,562.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,150 shares of company stock valued at $2,969,730. 1.90% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece was reported by Highlight Press and is the property of of Highlight Press. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://highlightpress.com/2019/02/14/dupont-capital-management-corp-has-732000-stake-in-biomarin-pharmaceutical-inc-bmrn.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
See Also: Different Types of Derivatives
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.